Analysts Offer Insights on Healthcare Companies: Akebia Therapeutics (NASDAQ: AKBA) and Matinas BioPharma (NASDAQ: MTNB)

By Ryan Adsit

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Akebia Therapeutics (NASDAQ: AKBA) and Matinas BioPharma (NASDAQ: MTNB) with bullish sentiments.

Akebia Therapeutics (NASDAQ: AKBA)

Aegis Capital analyst Difei Yang reiterated a Buy rating on Akebia Therapeutics (NASDAQ: AKBA) today and set a price target of $25. The company’s shares opened today at $13.77.

According to TipRanks.com, Yang is a 4-star analyst with an average return of 7.6% and a 46.7% success rate. Yang covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Protalix Biotherapeutics, and Spectrum Pharmaceuticals.

Akebia Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $23.

Matinas BioPharma (NASDAQ: MTNB)

In a report released today, Jason McCarthy from Maxim Group reiterated a Buy rating on Matinas BioPharma (NASDAQ: MTNB), with a price target of $6. The company’s shares opened today at $2.43.

McCarthy noted:

“Matinas announced positive data for MAT2203 (oral amphotericin) in azole- resistant mucocutanous candidiasis (i.e. oral thrush) at the ASM (American Society for Microbiology) conference demonstrating that in the first two patients treated, both patients experienced the target endpoint of >50% clinical response (data below). There are three key points to focus on: 1. Safety: MAT2203 was given for 6-8 weeks (vs 2 weeks or less of standard intravenous amphotericin) with no toxicity. 2. Effective Delivery: MAT2203 won’t release the amphotericin unless it’s effectively delivered to immune cells, which is demonstrated by the clinical responses in both patients. Cochleates are also taken up directly by fungi. 3. Two for Two so far. The study only requires 50% clinical response in 20% of patients, or 3/16. Conclusion: While this is only N=2 so far, the data are suggestive of early efficacy, which in our view represents early proof of concept given that these are long-time (>20 years) drug-resistant patients. As this is an open label study, more data should come soon. In addition, data from the fully enrolled VVC (Vulvovaginal Candidiasis) study is coming in a few weeks. Overall, the most important takeaway is safety.”

According to TipRanks.com, McCarthy is ranked 0 out of 5 stars with an average return of -11.7% and a 35.2% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as ImmunoCellular Therapeutics, Mateon Therapeutics Inc, and Soleno Therapeutics Inc.

Matinas BioPharma has an analyst consensus of Moderate Buy, with a price target consensus of $6.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.